Everolimus – 5 mg

Brand:
Cayman
CAS:
159351-69-6
Storage:
-20
UN-No:
Non-Hazardous - /

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that, as part of two distinct complexes (mTORC1 and mTORC2), plays pivotal roles in intracellular signaling.{15415,15559,24848} Everolimus is a hydroxyethyl ether rapamycin (Item No. 13346) derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.{24850,24847} It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.{24847} Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.{24847,24849} It also acts as an immunosuppressive agent in the context of organ transplantation.{24847,24846}  

 

Available on backorder

SKU: 11597 - 5 mg Category:

Description

A hydroxyethyl ether rapamycin derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM; orally available with superior pharmacokinetics and pharmacodynamics over rapamycin


Formal name: 42-O-(2-hydroxyethyl)-rapamycin

Synonyms:  RAD001

Molecular weight: 958.2

CAS: 159351-69-6

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Cell Biology|Cell Signaling|PI3K/Akt/mTOR Signaling